As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study titled: Elotuzumab in Relapsed/Refractory Multiple Myeloma: Final Survival Analysis from ELOQUENT-2.
Independent expert commentary is provided by Dr Hasib Sidiqi, a consultant haematologist at Fiona Stanley Hospital in Perth and an adjunct Associate Professor through Curtin Medical School.
Please login below to download this issue (PDF)